Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy

 Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy

Shots:

  • Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment
  • Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment for gene therapy in DMD & LGDM patients who have pre-existing antibodies to AAV
  • Imlifidase is an Ab-cleaving enzyme targeting IgG, inhibits an IgG-mediated immune response and has rapid onset of action within hours after administration, thus clearing the AAV-IgG Abs typically preclude dosing or re-dosing with AAV

Click here to read full press release/ article | Ref: Sarepta | Image: Wall Street Nation

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post